CTLA4 and melanoma: Among the melanoma patient cohort who received anti-CTLA-4 checkpoint blockade therapy, we observed a reduction in the gene expression level of NLRC5-dependent MHC class I and CD8+ T cell genes in non-responders versus responders (Fig. 1a).